Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: A method for detecting an antigen-specific antibody detection reagent, which includes a cationized, denatured antigenic protein immobilized on a solid-phase surface of a carrier material, is provided. The cationized, denatured antigenic protein has cationized SH groups formed from reaction with a cationizing agent. The detection reagent is capable of specifically binding to an antigen-specific antibody which binds to an epitope of the antigenic protein. The method includes contacting a sample containing the antigen-specific antibody with the detection reagent to bind the antigen-specific antibody with the detection reagent. A labeled secondary antibody is then added to allow the labeled secondary antibody to bind to the antigen-specific antibody; and the detection reagent bound with the antigen-specific antibody is detected.

Abstract: The present invention provides the following: a method for efficiently producing a reagent for detecting an antibody that specifically binds with an insoluble antigen protein present in a liquid sample; a reagent for antibody detection produced by the production method; and a use of the antibody. In a step for solubilizing an antigen protein, it is possible to efficiently solubilize and recover the antigen protein by using a cationizing agent; therefore, when compared to conventional methods, it is possible to efficiently produce a reagent for detecting an antibody that has bound to multiple antigen protein molecules in a carrier.

Abstract: This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody.

Abstract: For purposes of providing a pharmaceutical to be used for preventing or treating a TGF?-related disease by inhibiting signaling of TGF?, the present invention provides a TGF? inhibitor comprising, as an active ingredient, REIC/Dkk-3 protein or a partial protein thereof comprising a Cys-rich domain thereof, or a DNA encoding any of these proteins, and an agent for preventing or treating a TGF?-related disease containing the TGF? inhibitor.

Abstract: This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody.

Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.

Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.

Abstract: The present invention provides the following: a method for efficiently producing a reagent for detecting an antibody that specifically binds with an insoluble antigen protein present in a liquid sample; a reagent for antibody detection produced by the production method; and a use of the antibody. In a step for solubilizing an antigen protein, it is possible to efficiently solubilize and recover the antigen protein by using a cationizing agent; therefore, when compared to conventional methods, it is possible to efficiently produce a reagent for detecting an antibody that has bound to multiple antigen protein molecules in a carrier.

Abstract: The object of the present invention is to provide a novel thiosulfonate compound, a reversible cationization agent for protein and/or peptide, which can reversibly cationize a wider range of proteins and peptides with high stability of quality and accuracy and which are useful for a high degree of purification and recovery, as well as, a method for solubilization for protein and/or peptide using the agent. The present invention is a thiosulfonate compound having three or more cations derived from a quaternary ammonium group within one molecule.

Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.

Abstract: The object of the present invention is to provide a novel thiosulfonate compound, a reversible cationization agent for protein and/or peptide, which can reversibly cationize a wider range of proteins and peptides with high stability of quality and accuracy and which are useful for a high degree of purification and recovery, as well as, a method for solubilization for protein and/or peptide using the agent. The present invention is a thiosulfonate compound having three or more cations derived from a quaternary ammonium group within one molecule.

Abstract: The present invention provides a method of intracellular introduction by which a protein and/or peptide can be efficiently introduced into living cells and which makes it possible to effectively analyze the behavior and function of the protein and/or peptide introduced and can be suitably utilized/applied, for example in the technology “live cell imaging” which realizes the immunohistochemical visualization in living cells under physiological conditions. The method of intracellular introduction is a method for introducing a protein and/or peptide into a cell, which comprises the process of introducing a conjugate generated by binding of a compound adsorbable on a cell surface to a protein and/or peptide via a polysulfide bond into a cell and treating with a reducing agent.

Abstract: The invention relates to a method for transducing a pharmaceutical protein or polypeptide that may be fluorescently labeled into a cell by forming a conjugate with a cationic polymer having cation values of more than 2 and no more than 250 and transducing the conjugate into the cell. The protein or peptide pharmaceutical agent is directly covalently bound to the cationic polymer or is covalently bound to the cationic polymer through a bifunctional crosslinking agent.

Abstract: A test kit for intracellular introduction of a protein and/or peptide and a method of such intracellular introduction, make it possible for a protein and/or peptide to be introduced into cells efficiently and in an expedient manner while preventing the function of the introduction target protein and/or peptide from being reduced. The above test kit comprises a container containing a cationic group-containing polymer and a container containing a reagent for coupling or binding the cationic group-containing polymer to the protein and/or peptide, or comprises a container containing a cationized conjugate to be coupled to the protein and/or peptide. The above method comprises using a conjugate generated by coupling or binding a cationic group-containing polymer to a protein and/or peptide as a carrier for the introduction target protein and/or peptide.

Abstract: A test kit for intracellular introduction of a protein and/or peptide and a method of such intracellular introduction, make it possible for a protein and/or peptide to be introduced into cells efficiently and in an expedient manner while preventing the function of the introduction target protein and/or peptide from being reduced. The above test kit comprises a container containing a cationic group-containing polymer and a container containing a reagent for coupling or binding the cationic group-containing polymer to the protein and/or peptide, or comprises a container containing a cationized conjugate to be coupled to the protein and/or peptide. The above method comprises using a conjugate generated by coupling or binding a cationic group-containing polymer to a protein and/or peptide as a carrier for the introduction target protein and/or peptide.

Abstract: A conjugate which enables a protein or peptide to be transduced into cells and a method for transducing the protein or peptide into cells using the conjugate with time and amount controllability and efficiency.

Abstract: A conjugate which enables a protein or peptide to be introduced into cells and a method for introducing the protein or peptide into cells using the conjugate with time and amount controllability and efficiency.